Cargando…

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

BACKGROUND: The efficacy of rifaximin, a nonsystemic, gut‐targeted antibiotic for reducing non–constipation‐predominant irritable bowel syndrome (non‐C IBS) symptoms, has been demonstrated in one phase 2b and two phase 3 randomised, double‐blind, placebo‐controlled trials, but detailed data about ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., Forbes, W. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley-Blackwell 2014
Materias:	Irritable Bowel Syndrome
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112801/ https://www.ncbi.nlm.nih.gov/pubmed/24697851 http://dx.doi.org/10.1111/apt.12735

Ejemplares similares

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016)

A Swedish national adoption study of risk of irritable bowel syndrome (IBS)
por: Waehrens, Rasmus, et al.
Publicado: (2017)

Faecal incontinence—the hidden scourge of irritable bowel syndrome: a cross-sectional study
por: Atarodi, Sima, et al.
Publicado: (2015)

Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial
por: Ali, Ather, et al.
Publicado: (2017)

Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet
por: Vervier, Kevin, et al.
Publicado: (2022)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial
por: Tazzyman, Simon, et al.
Publicado: (2015)

Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial
por: Yan, Ran, et al.
Publicado: (2020)

Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)
por: Howell, Carol Angela, et al.
Publicado: (2022)

Gut microbiome composition and risk factors in a large cross-sectional IBS cohort
por: Agnello, Melissa, et al.
Publicado: (2020)

Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute
por: Carbone, Florencia, et al.
Publicado: (2022)

Development of a new version of the Bristol Stool Form Scale: translation, content validity, face validity, and reliability of the Persian version
por: Shokouhi, Nasim, et al.
Publicado: (2022)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
por: Bajaj, J S, et al.
Publicado: (2015)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
por: Cash, Brooks D., et al.
Publicado: (2017)

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
por: Jeppesen, P B, et al.
Publicado: (2011)

Irritant-induced Asthma Caused by Aerotoxic Syndrome
por: Roig, Jorge, et al.
Publicado: (2021)

The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation
por: Singh, Prashant, et al.
Publicado: (2022)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
por: Shah, Eric D, et al.
Publicado: (2018)

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
por: Shah, Eric D., et al.
Publicado: (2021)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
por: Pimentel, Mark, et al.
Publicado: (2015)

Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia
por: Singh, Prashant, et al.
Publicado: (2019)

Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis
por: Shah, Eric D., et al.
Publicado: (2021)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l7srjpcgcr75cfdhefn21mu9fk